Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration approval of a therapeutic protein produced by a plant cell-based expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Their pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets.